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Purpose: CXCR4 plays an important role in HIV infection, tumor progression, neurogenesis, and inﬂammation.
In-vivo imaging of CXCR4 could provide more insight in the role of this receptor in health and disease. The aim
of this study was to investigate [99mTc]O2-AMD3100 as a potential SPECT tracer for imaging of CXCR4.
Method: AMD3100 was labelled with [99mTc]pertechnetate. A cysteine challenge assay was performed to test
the tracer stability. Heterologous and homologous receptor binding assay and internalization assay were
performed in CXCR4 expressing Jurkat-T cells. Ex vivo biodistribution was studied in healthy mice at 30, 60,
and 120 min after tracer injection. Tumor uptake of the tracer was determined by microSPECT imaging in
nude mice xenografted with human PC-3 prostate tumor. Speciﬁcity of tracer uptake was determined by
blocking studies using an excess of unlabelled AMD3100.
Results: AMD3100 was labelled with technetium-99 m with a radiochemical yield of N98%. The tracer was
stable in PBS and mouse plasma for at least 6 h at 37 °C. Heterologous and homologous binding assays with
AMD3100 showed IC50 values of 240 ± 10 μM, and 92 ± 5 μM for [125I]SDF-1α and [99mTc]O2-AMD3100
respectively, with negligible receptor internalisation. The tracer showed high uptake in liver, lungs, spleen,
thymus, intestine and bone. Blocking dose of AMD3100.8HCl (20 mg/kg) decreased the uptake in these
organs (p b 0.05). [99mTc]O2-AMD3100 showed speciﬁc tumor accumulation in mice bearing PC-3 xenografts
model. Time activity curves (TAC) in AMD3100 pre-treated animals tracer showed 1.7 times less tumor
uptake as compared to control animals (p b 0.05).
Conclusion: [99mTc]O2-AMD3100 is readily labelled, is stable in plasma and displays a favourable binding
afﬁnity for the CXCR4 receptors. [99mTc O2-AMD3100 shows speciﬁc binding in organs with high CXCR4
expression and in CXCR4 positive tumors. These results justify further evaluation of this radiopharmaceutical
as a potential biomarker for the non-invasive imaging of CXCR4 receptors.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
The chemokine receptor 4 (CXCR4) is a member of the α-
chemokine family and belongs to a larger superfamily of receptors
known as G protein coupled receptors (GPCRs). Stromal cell-derived
factor 1α (SDF-1α/CXCL12) is the natural ligand for CXCR4
receptors. CXCR4 is widely expressed by hematopoietic and non-
hematopoietic cell types, including T cells, B cells, neutrophils,
monocytes, CD34+ cells, endothelial cells, neurons, and astrocytes.
CXCR4 and CXCL12 play an important role in the regulation of
leukocyte trafﬁcking, hematopoiesis, angiogenesis, cancer, and viral
pathogenesis [1–7]. In addition, CXCR4 and its cognate ligand are
also expressed in the brain, where they are involved in develop-icine and Molecular Imaging,
ingen, Hanzeplein 1, 9713 GZ
+31 50 3611687.
).
l rights reserved.ment, migration, differentiation, neuroplasticity and proliferation of
glia and neuronal cells. Recently, possibility has been raised that
CXCR4 and CXCL12 might act as neurotransmitter or neuromodu-
lator [8–10]. Both CXCR4 and CXCL12 knockout mice show loss of
functioning B cells, vascularisation, and abnormal development of
brain areas such as hippocampus, neocortex, and cerebellum
[3,11,12].
CXCL12 and its receptor CXCR4 mediate the recruitment of
immune cells to sites of inﬂammation and infection. Consequently,
they are upregulated in several disease conditions, including
allergy, infectious diseases, atherosclerosis, multiple sclerosis,
rheumatoid arthritis, and psoriasis [13–15]. CXCR4 and CCR5 were
discovered to serve as the principal co-receptors that mediate the
entry of the human immunodeﬁciency virus (HIV) into the immune
cells [16]. It has been proposed that HIV-induced neuronal death
and dementia could be mediated by CXCR4 as HIV co-receptors
[17–19]. The expression of CXCR4 receptors in various physiological
and pathological conditions makes them potential candidates for
drug development.
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receptors also play a signiﬁcant role in tumor growth and metastasis.
More than 20 different kinds of human tumors overexpress CXCR4
and CXCL12 [6,20–22]. An increased expression of CXCR4 and its
ligand CXCL12 is associated with a high risk of metastases [23–25].
This could make CXCR4 an important biomarker to identify primary
tumors that are likely to metastasize [26,27]. Furthermore, the
overexpression of these chemokine receptors can play a role in the
metastatic destination of tumor cells [28,29]. Inhibition of CXCR4/
CXCL12 signalling resulted in reduced metastatic potential in various
animal tumor models [30–32]. As a consequence, a number of CXCR4
inhibitors are now under clinical investigation.
Non-invasive imagingmodalities canprovideabetterunderstanding
of the role of CXCR4 in health and disease. For example, an in vivo
imaging tool might be helpful to identify patients with tumors
expressing high levels of the CXCR4 receptor, thus likely to respond to
CXCR4 based therapies. Such a tool can also be utilised for early
diagnosis and treatment responsemonitoringof CXCR4positive tumors.
A number of attempts have been made to non-invasively image CXCR4
receptors, using nuclear imaging techniques. As a result, several
positron emitting tomography (PET) and single photon emitting
computed tomography (SPECT) based imaging probes for CXCR4
expression have been evaluated in animal cancer models [33–37].
AMD3100 is a speciﬁc and selective CXCR4 receptor antagonist; it
is a prototype non-peptide, small molecule inhibitor [38]. AMD3100
has been used in clinical trials as an anti-HIV therapy [39]. In addition,
it was shown to be an effective mobiliser of hematopoietic stem cells
in healthy volunteers and in multiple myeloma and non-Hodgkin’s
lymphoma patients [40,41]. Furthermore, AMD3100 effectively in-
hibits autoimmune collagen-induced arthritis, neuroinﬂammation
and asthma in animal models [42]. Compelling evidence suggests that
the aspartic acid residues Asp171 and Asp262 of CXCR4 play a key role
in the interaction between receptors and AMD3100 [43]. Recently, a
brief communication on imaging of CXCR4 by SPECT agent [99mTc]O2-
AMD3100 was published, but proper in vitro and in vivo evaluation
has not been described so far [44]. In this paper, we report the
radiolabeling and quality control of [99mTc]O2-AMD3100. Further-
more, we describe here the in vitro and in vivo evaluation of [99mTc]
O2-AMD3100 as a SPECT tracer for CXCR4.
2. Materials and Methods
2.1. General
All the reagents and solvents were purchased from Sigma Aldrich
chemical company and used without further puriﬁcation. 1H NMR
was acquired with a Varian Oxford 400 MHz NMR instrument.
Recombinant CXCL12 was purchased from R&D System. Na[99mTc]
O4 was produced by elution of the 99Mo/99mTc generator according to
themanufacturer’s instructions. Carrier-free sodium iodide [Na125I] in
phosphate buffer was obtained from MDS Nordion. AMD3100
octahydrochloride hydrate (AMD3100.8HCl) was prepared according
to a method previously described in the literature [35,38,45,46].
2.2. Labelling of AMD3100 with Na99mTcO4
Radiolabeling of AMD3100 was performed with sodium [99mTc]
pertechnetate in the presence of stannous chloride (SnCl2). In brief, 10
μL of the AMD3100 solution (10 mg/mL in H2O) and 300 μl of
SnCl2.2H2O solution (1 mg/mL in water) were prepared freshly and
added to the reaction vial. The pH of the solution was adjusted to 7.2
with 1 M sodium citrate buffer (~5 μL). Sodium [99mTc]pertechnetate
(400 MBq) was added to the mixture and incubated for 20 min at
room temperature [44]. For the determination of conversion and
radiochemical purity, samples were analysed by thin layer chroma-
tography (TLC) using Whatman paper No. 3. TLC analyses wereperformed using 0.9% NaCl, methyl ethyl ketone (MEK) or ammonia:
water:ethanol (1:5:5) as the mobile phase. To obtain the optimum
labelling yield of the [99mTc]O2-AMD3100 complex, the reaction
conditions were optimised for different parameters, such as the
concentrations of AMD3100 and SnCl2, incubation period and the pH
of the reaction mixture. The tracer was diluted with PBS (pH 7.4) to
obtain the required concentration for cell and animal experiments.2.3. Labelling of [125I] SDF-1α
[125I]SDF-1α was prepared by reaction of SDF-1α with sodium
[125I]iodide in the presence of N-bromosuccinimide (NBS) as a mild
oxidizing agent [47]. Prior to iodination, the SDF-1α was dissolved in
PBS at a ﬁnal concentration of 1 mg/ml. The NBS solution in water
(0.25 mg/ml) was prepared freshly. The reaction mixture was
prepared by mixing 50 μl of SDF-1α (5 μg), 25 μl tris buffer
(pH 7.4), 20 μl (40 MBq) sodium [125I]iodide and 10 μl of freshly
prepared NBS. The mixture was vortexed for 30 s and allowed to
stand for 5 min at room temperature. After the reaction was stopped
by dilution with PBS, the labelled protein was separated from free
[125I]iodide using a PD-10 size exclusion cartridge (GE, Healthcare)
that was pre-conditioned with PBS. The column was eluted with PBS
and the fraction with maximum amount of radioactivity was collected
and stored for further use. The percentage of free [125I] iodide was
determined using a trichloroacetic acid (TCA) precipitation assay. The
percentage of free [125I]iodide was found to be less than 1%.2.4. Partition co-efﬁcient
To a mixture of 0.5 ml n-octanol and 0.5 ml of sterile water, 10 μL
of the tracer solution was added, and the biphasic solution was mixed
well. The mixture was incubated at 37 °C for 1 h and subsequently
centrifuged at 3000 rpm for 5 min. 100 μl aliquots were collected
from each layer and radioactivity was counted in a γ-counter
(Compugamma CS1282, LKB-Wallac, Turku, Finland). The log value
of the octanol–water partition coefﬁcient is reported as the average of
three independent experiments.2.5. In vitro stability
The stability of the [99mTc]O2-AMD3100 complex was measured
by diluting a solution containing more than 98% pure [99mTc]O2-
AMD3100 complex with PBS or mouse plasma. For this purpose, fresh
blood samples were collected from mice. After the blood was
centrifuged at 3000 rpm, plasma was collected and divided into
250 μl aliquots. 10 μl of [99mTc]O2-AMD3100 was added to 240 μl of
fresh plasma or PBS and incubated at 37 °C. The percentages of free
and AMD3100 bound 99mTc were measured at different time points
(1, 2, 4, 6, and 24 h) by TLC. In addition, a cysteine challenge assaywas
performed in order to check the in vitro stability of the complex. The
tracer was incubated at 37 °C for 60 min at different cysteine to
AMD3100 molar ratios (up to 500:1). At the end of the incubation
time, the reaction mixture was analysed by TLC as described above.
Furthermore, stability of tracer in 0.5 M NaOH and HCl was evaluated
by incubating tracer up to 3 h at room temperature.2.6. Cell cultures
The CXCR4-positive Jurkat-T and PC-3 cell lines were purchased
from ATCC (Manassas, VA, USA). Jurkat-T and PC-3 cells were cultured
in RPMI 1640 supplemented with 10% FCS. Cells were maintained at
37 °C in humidiﬁed 5% CO2 atmosphere.
Fig. 1. A) Labelling yield as function of SnCl2 concentration. Conditions: concentration
AMD3100 0.135×10α3 M, pH 7, incubation time 20 min, temperature 25 °C. B)
Labelling yield as function of AMD3100 concentration. Conditions: concentration
SnCl2 0.5×10−3 M, pH 7, incubation time 20 min, temperature 25 °C.
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Both heterologous and homologous competition binding assays
were performed on Jurkat-T cells in order to test the speciﬁc binding
[34–36,48]. Cells were harvested and seeded in 12-well plates at a
density of 105 cells per well. After 24 h, the cells were washed twice
with PBS. The heterologous binding assay was performed by adding
an increasing concentration of unlabelled AMD3100 in the range of
10−6–10−3 M to the cells, followed by incubation with 100 pM [125I]-
SDF-1α in a 1000 μl binding buffer (PBS pH 7.4, supplemented with
50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2, 0.5% BSA) for 3 h at 4 °C.
After incubation, cells were quickly washed two times with 500 μl
cold binding buffer and cell-associated radioactivity was measured by
an automated gamma counter. Similarly, a homologous binding assay
was done using 100 nM of [99mTc]O2-AMD3100. Cells were incubated
for 1 h at 37 °C in 1000 μl binding buffer (PBS containing, 5 mM
MgCl2, 1 mM CaCl2, 0.25% BSA). The IC50 values were determined by
nonlinear regression analysis, using GraphPad Prism 5.0. All exper-
iments were performed in triplicate.
2.8. Receptor internalization assay
Jurkat-T cells were seeded in 6-well plates (105 cells per well).
After 24 h cells were washed two times with PBS. Cells were
incubated with [99mTc]O2-AMD3100 for 2 h at 4 °C. Unbound
radioactivity was removed by washing with cold PBS. Cells were
then incubated with pre-warmed binding buffer and incubated at
37 °C for different time intervals to allow for receptor internalization.
The membrane bound tracer was removed by washing with acid
buffer (50 mM glycine-HCl, 10 mM NaCl, pH 2.8). The cells were
washed twice with ice-cold binding buffer and subsequently lysed
with 1 M NaOH at 37 °C. The lysate was collected to determine the
internalization fraction. The radioactivity in each fraction was
measured with a γ-counter and the percentage internalization was
calculated according to the formula: % internalization = [activity in
lysate/(activity in lysate + activity in membrane bound fraction)]
* 100%.
2.9. Animals
Male Balb/c mice (3–4 weeks old) were obtained from Harlan
(Lelystad, The Netherlands). The animals were provided with
standard laboratory food and water. All the animal studies were
approved by the institutional ethics committee for Animal Research,
of the University of Groningen (DEC protocol No. 6073A) and
executed in accordance with the regulations of Dutch law on animal
welfare. The immune-competent wild type Balb/cmice were used for
ex vivo biodistribution to provide information about tracer uptake in
immune-related organs, whereas tumor bearing male Balb/c Athymic
nu/nu immune-compromised animals were used for in vivo SPECT
imaging to demonstrate tumor targeting of the tracer. Human PC-3
prostate tumor cells were grafted in nude athymic Balb/c mice by
subcutaneous inoculation, PC-3 cells (2 × 106 cells) in a 1:1 mixture
of matrigel and RPMI 1640 medium containing 10% FCS were injected
subcutaneously into the right front ﬂank. Xenografts were allowed to
grow during a period of 2–3 weeks, the tumor size was measured
weekly using vernier calliper. When the tumor volume had reached a
size of about 200 ± 25 mm3 (weight of the tumor at end of scan
250 ± 10 mg n = 6), the animals were used for SPECT imaging.
2.10. Biodistribution studies
Sixteen healthy Balb/c mice were randomly divided into four
groups of four animals. Isoﬂurane (1.5% in medical air) inhalation was
used as method of anesthesia during injection of the tracer. All groups
were injected with 5–10 MBq of [99mTc]O2-AMD3100 via the penilevein. At 30, 60, or 120 min post injection (group 1, 2 and 3
respectively), the animals were sacriﬁced and various organs of
interest (heart, liver, spleen, lung, blood cells, bone, thymus, pancreas,
small and large intestine, stomach, kidney and bladder) were
harvested and weighed. The radioactivity in these tissues was
determined with a γ-counter.
In order to determine the speciﬁc binding of the tracer, four mice
(group 4) were injected with a blocking dose of AMD3100.8HCl
(20 mg/kg) s.c. 30 min before injection of the radiotracer. One hour
after injection of the tracer, the animals were sacriﬁced. Blood and
organs were collected, weighed, and counted as described above.
Tracer uptake is expressed as a percentage of injected dose/gram of
tissue (% ID/g)
2.11. MicroSPECT Imaging
Imaging experiments were performed on PC-3 xenograft bearing
Athymic nu/nu mice (n = 6). After the animals were anaesthetized
with 1.5% of isoﬂurane in medical air, [99mTc]O2-AMD3100 (120 ±
10 MBq) was injected intravenously via the penile vein. Immedi-
ately after tracer injection, the animals were placed in a prone
position in a three-headed SPECT camera (MILabs, U-SPECT-II,
Utrecht, The Netherlands) equipped with a multi-pinhole high-
resolution collimator (pinhole diameter 0.6 mm, spatial resolution
about 0.4 mm). The ﬁeld of view was set to include the tumor and
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animal, dynamic data were acquired for 60 min (12 frames, 5 min
per frame). Subsequently, a whole body static image was collected
over a period of 10 min. The imaging data were stored digitally in
list mode.
The SPECT imaging study was performed as a longitudinal
experiment, in which each animal was scanned twice. On day 1,
animals were investigated under baseline conditions. On day 2, the
SPECT scan was repeated on the same animal after a blocking dose of
unlabeled AMD3100.8HCl (20 mg/kg) was administered s.c 30 min
before tracer injection. The imaging data were acquired using the
same procedure as described above. Only after the second scan,
animals were terminated and tumor and other organs were collected
for histopathological analysis.
Images were reconstructed with U-SPECT-Rec v 1.34i3 software
(MILabs, Utrecht, The Netherlands) with a pixel-based ordered
subsets expectationmaximum (POSEM) algorithm. The SPECT images
of the tumor bearingmicewere loaded in the Inveon analysis software
(Siemens). Regions of interest were drawn around the tumor on all
slices that showed part of the tumor. Thus, a volume of interest was
generated by combining the 2 dimensional ROIs. The radioactivity
concentration in the volume of interest was measured and convertedFig. 2. A) In vitro stability test of [99mTc]O2-AMD3100 in PBS and mouse plasma at 37 °C for
molar ratio of cysteine to AMD3100 incubation 60 min at 37 °C.to % ID/g by correction for the injected dose. It is assumed that 1 mm3
of tissues equals 1 g. Results are expressed as mean. ± SD.
2.12. Immunohistochemistry
Tumor and other organs from the imaging experiments were
collected, snap-frozen in liquid nitrogen and stored in a freezer at
−80 °C until required for further use. All the tissues were cut in 5-μm-
thick sections for H&E and immunostaining. The sectionswere ﬁxed in
acetone and immersed in PBS solution containing 0.5% hydrogen
peroxidase for 30 min to block endogenous peroxidase activity. The
sections were then incubated in 2.5% normal serum to reduce non-
speciﬁc binding, and then sections were incubated overnight at 4 °C
with primary rabbit polyclonal anti-CXCR4 antibody (Abcam, clone
2074; Cambridge, UK) at a dilution of 1:500. A negative control
without the primary antibody was included to check the speciﬁcity of
the antibody. The sections were processed using standard horseradish
peroxidase (HRP) conjugated secondary and tertiary antibody
according to the manufacturer’s recommendations (Dako, Belgium).
Diaminobenzidine (DAB) was used as a chromogen, and hematoxylin
was used for counterstaining. After washing, cover slips were
mounted and sections were examined under a Leica microscope.different time points. B) Cysteine challenge assay of [99mTc]O2-AMD3100 at increasing
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Statistical analyses were performed using Excel 2003 (Microsoft)
and GraphPad prism 5. All the data represent the mean ± standard
deviation (SD), differences in tracer accumulation between controls
and the AMD3100 treated group were analyzed using an unpaired
two-sided student’s t-test in case of biodistribution and a paired two-
sided student’s t-test for the imaging studies. Data were considered
statistically signiﬁcant when p values were smaller than 0.05.
3. Results
3.1. Radiolabelling of AMD3100
Although radiolabelling of macrocyclic cyclams with [99mTc]
pertechnetate has been reported in the literature [44,49,50], we ﬁrst
aimed to optimize the labelling parameters for the incorporation of
99mTc into the bicyclam under reducing conditions. To achieve anFig. 3. A) In vitro heterologous and homologous AMD3100 displacement assay with [125I]SDF
B) Receptor internalization assay in Jurkat-T cells. Cells were incubated with [99mTc]O2-AM
indicated time points to permit the internalization of receptors.optimum yield of [99mTc]O2-AMD3100, effects of pH, concentration of
SnCl2 and AMD3100 were investigated. Labelling yield was strongly
dependent on pH, as labelling efﬁciencies of 19% ± 3% (n = 5),
97% ± 2% (n = 5) and 26% ± 1% (n = 5) were obtained when a 1 M
citrate buffer at pH 3, 7 and 11 was used, respectively. The effect of
stannous chloride concentration on radiolabeling was studied in the
range of 10−5 M to 10−1 M. Fig. 1A shows that the radiolabeling yield
increases with an increasing stannous chloride concentration, reach-
ing a plateau at 10−3 M with a maximum yield of N98%. Similarly, the
effect of AMD3100 concentration was determined using amounts of
the ligand that ranged from 10−6 M to 10−2 M. An increasing yield
was observed as a function of increasing concentrations of AMD3100
until a plateau was reached at 10−4 M, corresponding to a maximum
labelling yield of N 98% (Fig. 1B). Under optimal reaction conditions
(pH 7, 0.5 mM SnCl2, 0.135 mM AMD3100, reaction time 20 min at
room temperature), a labelling yield of 98% ± 1% was achieved, with
a speciﬁc activity of 8400–8800 MBq/μM. These conditions were used
for labelling of AMD3100 for the in vitro and in vivo experiments.-1α and [99mTc]O2-AMD3100, respectively. The experiment was performed in triplicate.
D3100 for 1 h at 4 °C. Cells were subsequently washed and warmed at 37 °C for the
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The quality control of [99mTc]O2-AMD3100 was performed by TLC
usingWhatman No. 3 paper. When 0.9% NaCl was used as the solvent,
retention factors (Rf) were 0.81 ± 0.02 for [99mTc]O2-AMD3100 and
0.86 ± 0.01 for free Na[99mTc]O4. When 2-butanone was used as the
solvent, Rf were as follows: 0.11 ± 0.06 [99mTc]O2-AMD3100 and,
0.89 ± 0.06 for free Na[99mTc]O4. In order to determine the presence
of reduced hydrolysed technetium colloids (TcO2−), TLC was
performed in ammonia:water:ethanol (1:5:5). The colloids remained
at the origin, while the AMD3100 complex along with free [99mTc]Fig. 4. A) Biodistribution data of selected organs from the normal BALB/Cmice injected with 5
are represented as mean ± SD of 4 animals. B) Ex vivo biodistribution and blocking studi
without blocking dose of AMD3100.8HCl (20 mg/kg). Data are represented asmean ± SD of
two-tailed students t-test. C) Typical radio-TLC analysis of [99mTc]O2-AMD3100 usingWhatm
be stable in i) plasma (98% intact) and ii) urine (97% intact).pertechnetate migrated with the solvent front. After the optimisation
of reaction, the formation of the colloids (TcO-2) and free [99mTc]
pertechnetate was found to be less than 1% in total, whereas the
amount of [99mTc]O2-AMD3100 was N99%. Hence, we decided that
further puriﬁcation of the tracer by HPLC was not required. The
partition coefﬁcient of the tracer was determined in a mixture of n-
octanol and water. The logP value was found to be−2.60 ± 0.25, this
indicates that the tracer is highly hydrophilic.
The in vitro stability of the [99mTc]O2-AMD3100 complex was
studied in PBS and mouse plasma at different time intervals. The
tracer was stable in PBS and plasma for at least 6 h at 37 °C (Fig. 2A).MBq [99mTc]O2-AMD3100 and terminated at different time points. Biodistribution data
es of [99mTc]O2-AMD3100 in normal BALB/C mice at 1 h after tracer injection with or
4 animals, * (p b 0.05), *** (p b 0.001) statistical analysis was performed by unpaired by
an No. 3 paper and saline as the eluent. Two hours post injection the tracer was found to
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still intact in mouse plasma. In addition, the stability of the
preparation was tested in a challenge assay, in which the tracer was
incubated with an increasing amount of cysteine at 37 °C for 1 h.
Negligible decomposition of [99mTc]O2-AMD3100was observed when
the complexwas incubatedwith up to 50-fold excess of cysteine. Even
when the labelled complex was exposed to a 500-fold excess of
cysteine, it only released 20% of the activity (Fig. 2B). Furthermore,
N90% of the tracer was still intact, when it was incubated with 0.5 M
NaOH or 0.5 MHCl for 1 h at room temperature. However, there was a
signiﬁcant loss of the integrity of the tracer after 3 h of incubation
(data not shown). Taken together, [99mTc]O2-AMD3100 was consid-
ered sufﬁciently stable for further evaluation.
3.3. In vitro binding and internalization
The Jurkat-T cell line naturally expresses CXCR4 [35]. To study the
binding of the radiopharmaceutical to CXCR4 receptor, a heterologous
and a homologous binding assay was performed in Jurkat-T cells,
using [125I]SDF-1α and [99mTc]O2-AMD3100 as the CXCR4 speciﬁc
radioligand, respectively. Radioligand binding was plotted in sigmoid
curves for the both radioligands as a function of increasing
concentration of AMD3100 (Fig. 3A). The measured IC50 values wereFig. 4 (cont240 ± 10 μM, and 92 ± 5 μM for [125I]SDF-1α and [99mTc]O2-
AMD3100, respectively. The binding and internalization assays
showed that tracer binding to the cell membrane bound receptor
reaches a plateau in 60 min (Fig. 3B). In addition, there is hardly any
cytosolic accumulation of tracer after an incubation period of 4 h,
indicating that internalization of the receptors after binding of the
tracer is negligible.
3.4. Ex vivo biodistribution
The results of the ex vivo biodistribution of [99mTc]O2-AMD3100
in healthy mice is shown in Fig. 4A. The percentage of injected
dose/gram of tissues (% ID/g) of the tracer was determined in
various organs at 30, 60, and 120 min post injection. In immune-
related organs with a high density of CXCR4 expressing cells, such
as the bone (marrow), spleen, liver and thymus, tracer uptake was
highest at 1 h post injection and decreased thereafter, with most
activity being eliminated by 2 h. In contrast, radioactivity in blood
gradually decreased over time from the ﬁrst time point onward.
Hepatic uptake was modest, whereas accumulation in the kidney
and bladder (6% and 58% ID/g respectively) was high, due to rapid
clearance of radioactivity from the blood pool via renal–urinary
route. Moreover, negligible accumulation was detected in brain andinued).
514 S.V. Hartimath et al. / Nuclear Medicine and Biology 40 (2013) 507–517muscle. When the uptake over time was evaluated, only the kidney
and bladder showed increased tracer uptake for at least 2 h. The
administration of a blocking dose of AMD3100 resulted in a
decrease in uptake of the tracer (Fig. 4B) in organs such as liver
(61%), intestine (72%), thymus (91%), spleen (62%), and bone (52%).
This reduction of tracer uptake was statically signiﬁcant (p b 0.05)
in all of these organs.
When an excess of unlabelled AMD3100 was injected prior to
[99mTc]O2-AMD3100 injection, nonspeciﬁc uptake in the kidneys was
increased further, indicating that after blocking of the receptor, a
greater fraction of the injected dose is cleared via the kidneys. The
tracer was stable in vivo, as plasma and urine analysis by TLC showed
that the tracer remained intact in plasma (N98%) for 2 h and was
eliminated as intact tracer (N97%) into the urine (Fig. 4C).Fig. 5. Immunohistochemistry demonstrating the expression of CXCR4 protein in various or
the tissues were found to be positive whereas pancreas showed negative.3.5. Immunohistochemistry
The morphological analysis of the xenografts revealed viable
tumor tissue, with a few cells undergoing mitosis. In order to verify
the presence of CXCR4 in PC3 tumor xenografts, we performed
immunostaining of the resected tumors. The moderate cytoplasmic
expression of CXCR4 protein was found to be homogeneously
distributed throughout the tumor. For comparison, immunohisto-
chemistry was also performed on liver, lungs, spleen, intestine and
pancreas. Staining reveled a strong to moderate homogenous
expression of CXCR4 in liver, lung, intestine and spleen, but not in
the pancreas. The tissues that expressed CXCR4, as determined by
immunohistochemistry also showed speciﬁc tracer uptake in the ex-
vivo biodistribution study (Fig. 5).gans: i) PC-3 tumor, ii) liver, iii) lung, iv) spleen, v) small intestine and vi) pancreas. All
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Typical [99mTc]O2-AMD3100 small animal SPECT images of mice
bearing PC-3 tumors are presented in Fig. 6A. Based on the
biodistribution studies, a dynamic scan of 60 min of the tumor region
was acquired, followed by a 10 min whole body scan. Scans were
acquired with and without prior administration of an excess of
unlabelled AMD3100. Prominent accumulation of tracer was seen in
the tumor in all the frames of the dynamic SPECT scan in the absence
of a blocking agent. In addition, high uptake was also seen in liver,
spleen, and lungs. Injection of an excess of the blocking agent prior toFig. 6. A) CXCR4 imaging in PC-3 tumor xenografts bearing mice with [99mTc]O2-AMD3100. T
post injection. Coronal view of an athymic nudemice bearing a tumor, A) control SPECT of a co
blocking dose of AMD3100.8HCl (20 mg/kg). D) Digital image of the blockedmice. Arrow ind
by SPECT between 5 and 60 min post injection of [99mTc]O2-AMD3100. The ROI values were c
5 animals, * (p b 0.05).tracer injection reduced the uptake in tumor and other CXCR4 positive
organs, while kidneys remained visible.
Time activity curves were generated from the SPECT images,
regions of interest (ROIs) were drawn around the tumors and the
amount of radioactivity in the ROIs was quantiﬁed and converted to %
ID/g. The data showed a different kinetic behaviour of the tracer in
tumor between control and AMD3100-treated mice (Fig. 6B). In the
tumor of control mice, the highest accumulation of the tracer was
reached within 5 min post injection, subsequently activity decreased
exponentially. In case of AMD3100-treated animals, the initial tracer
uptake was lower than in controls, but the tracer showed similarracer was injected through penile vein, andwhole body images were acquired at 70 min
ntrol animal B) digital image of control animal. C) SPECT image after administration of a
icates the tumor. B) Time–activity curves of PC3 tumors in tumor-bearingmice, acquired
orrected for the injected dose and converted to % ID/g and expressed as mean ± SEM of
516 S.V. Hartimath et al. / Nuclear Medicine and Biology 40 (2013) 507–517washout. The difference in tracer uptake between both groups of
animals was statistically signiﬁcant at all the time points (p b 0.05).
Furthermore, the area under the curve (AUC) of the control tumor (5–
60 min) was 11.1 ± 2.4 min, which is signiﬁcantly higher than the
AUC of the AMD3100-treated tumor 6.6 ± 1.6 min (p b 0.05).4. Discussion
Because of its availability from generator systems and the relative
easy of radiometallation chemistry, the SPECT agent 99mTc has gained
wide interest in the ﬁeld of radiopharmaceutical chemistry. In this
study, we aimed to radiolabel the drug AMD3100 with 99mTc and
evaluate it as a potential tracer for SPECT imaging. After optimization
of the procedure, AMD3100 was readily labelled, giving [99mTc]O2-
AMD3100 in high yield. The AMD3100 has cyclam ring which is
similar to the DOTA or NOTA ring structure and suitable for the
radiometal chemistry. Recently, a copper [64Cu] labelled AMD3100
has been evaluated as a PET tracer [35,37]. However, the radio-
synthesis was relatively time-consuming and in-vitro binding assay in
Jurkat cells resulted in IC50 value in micromolar range. Generally, the
copper complexes are thermodynamically unstable and are more
prone to release the metal ion in vivo; as a result most of copper binds
to plasma protein and give high background.
We anticipated that the incorporation of the 99mTc metal ions into
the cyclam ring would increase the binding afﬁnity of the AMD3100
towards CXCR4. However, the in vitro binding study showed nearly a
3 fold higher IC50 value in the homologous binding assay with [99mTc]
O2-AMD3100, in comparison to the reported values for [64Cu]2+-
AMD3100 [35]. In line with this it was demonstrated that the
incorporation of a transition metal ions, such as Ni2+, Zn2+ and Cu2+,
into the macrocyclic rings of cyclams and bicyclams enhances the
binding afﬁnity for the CXCR4 receptors by 50, 36 and 7 fold
respectively, whereas incorporation of bigger metal ions, such as
Pd2+, decreases the binding afﬁnity of AMD3100 [43]. This may be the
reason for the reduced IC50 values in the homologous binding assay, as
compared to the Cu2+ complex. Since Cu2+ increases the binding
afﬁnity of AMD3100 to CXCR4 by 7 fold, the 3 fold decrease in IC50 of
[99mTc]O2-AMD3100 compared to the Cu2+ complex indicates that
incorporation of TcO+2 still increases the binding afﬁnity of labelled
AMD3100 compared to free AMD3100. Thus, we anticipated that the
binding afﬁnity of [99mTc]O2-AMD3100 is sufﬁcient to warrant further
evaluation in vivo.
Our tracer was found to be stable both in vitro and in vivo. The
transchelation to cysteine is a principle main reason for in vivo
instability of most of 99mTc-labelled tracers. In our case, the [99mTc]
O2-AMD3100 was stable even at higher molar ratio of cysteine and
displayed thermodynamical stability. The uptake of tracer was
observed in liver, bone marrow, lymph nodes, spleen, intestine and
thymus. It has been reported that these organs express relatively high
levels of the CXCL12 ligand, and consequently accumulate high
number of CXCR4-positive cells, such as hematopoietic stem/
progenitor or immune cells. CXCR4 expression in these organs was
conﬁrmed by immunostaining [25,50–55]. The blocking experiment
shows that accumulation in these tissues was speciﬁc. Moreover, we
observed negligible tracer uptake in the brain, even though brain has
relatively high expression of CXCR4 receptors, which is due to the
polar nature of the tracer [9]. The tracer uptake in most CXCR4 poor
organs decreasedwith time, with the exception of kidney and bladder.
This indicates that the tracer was mainly excreted via the renal
pathway, as could be expected based on its high hydrophilicity. After
2 h, most radioactivity was cleared from the body as intact tracer, as
no radioactive metabolites were found in urine. Previous preclinical
studies have also shown that, the native AMD3100 has fast
pharmacokinetics and is eliminated unchanged through the renal
route [40,56].Based on the biodistribution data, an imaging study was
performed in prostate tumor xenografted mice. We selected the PC-
3 prostate cancer model, because this tumor cell line has constitutive
expression of CXCR4 receptors [57]. The moderate basal expression of
CXCR4 in these cells better reﬂects the normal physiology in a clinical
situation than the genetically engineered tumors with high over-
expression of CXCR4 that are frequently used in this ﬁeld of research.
SPECT imaging could clearly visualize the accumulation of the tracer
in the tumor. The imaging study also demonstrated the [99mTc]O2-
AMD3100 uptake was speciﬁcally receptor mediated, as the accumu-
lation was blocked by an excess of cold AMD3100. The speciﬁc
accumulation of the tracer in tumor tissue was supported by
immunostaining of tumor sections, showing homogenous CXCR4
expression in the tumor.
Tumor time–activity curves of the control and AMD3100-treated
animals also conﬁrmed speciﬁc binding of [99mTc]O2-AMD3100, as the
AUC of the control tumors is 1.7 times higher when compared to the
AUC of AMD3100 saturated tumors (p b 0.05). Apart from the tumor,
a high uptake of the tracer was also observed in liver and lungs, due to
the relatively high basal expression of CXCR4 in these organs,
indicating that [99mTc]O2-AMD3100 may not be suitable for diagnosis
of lung and liver metastasis. Ex vivo biodistribution data of the
previously published [64Cu]2+-AMD3100 were slightly different from
the data for [99mTc]O2-AMD3100 obtained in our study, indicating
that the radio-isotope does affect the in vivo properties of the tracer.
For [64Cu]2+-AMD3100, accumulation of tracer increased over a
longer period of time in all tissues especially in the liver and lymph
nodes (up to 6 h), whereas accumulation of [99mTc]O2-AMD3100
reaches a maximum at 1 h. This might be explained by the lower
binding afﬁnity of the technetium complex and a faster clearance
rate [35].
5. Conclusion
The ex vivo biodistribution and SPECT studies have revealed that
[99mTc]O2-AMD3100 primarily accumulates in organs with high
expression of CXCR4 and that in vivo tracer accumulation in these
organs is speciﬁc. In addition, the tracer is easy to prepare and
technetium-99m is widely available and inexpensive. These aspects
justify further evaluation of this radiopharmaceutical as a potential
marker for the non-invasive imaging of CXCR4 receptors.
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